Icahn Pursues Seat on ImClone’s Board

Billionaire investor Carl Icahn said that he wanted to be a member of ImClone Systems Inc.’s board and that the biotechnology company’s chairman, David M. Kies, should not be reelected.

Icahn, 70, said acting Chief Executive Joseph Fischer should be replaced by someone with a “significantly stronger background in biotechnology,” according to a regulatory filing.

ImClone, known for the Martha Stewart trading scandal, had offered to list Icahn, an Icahn employee and two Icahn associates on the management’s slate for election next month. ImClone, whose only product is cancer medicine Erbitux, made the overture after abandoning a six-month search for a buyer.